Kodiak Sciences Stock Today
| KOD Stock | USD 5.90 0.11 1.90% |
Performance21 of 100
| Odds Of DistressLess than 44
|
Kodiak Sciences is trading at 5.90 as of the 21st of November 2024, a 1.90 percent increase since the beginning of the trading day. The stock's lowest day price was 5.66. Kodiak Sciences has about a 44 percent probability of financial distress in the next few years of operation but had a somewhat solid performance during the last 90 days. Equity ratings for Kodiak Sciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of August 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of October 2018 | Category Healthcare | Classification Health Care |
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. Kodiak Sciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 52.62 M outstanding shares of which 1.3 M shares are now shorted by investors with about 5.19 days to cover. More on Kodiak Sciences
Moving together with Kodiak Stock
Moving against Kodiak Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Kodiak Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | Hong Liang | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsKodiak Sciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Kodiak Sciences' financial leverage. It provides some insight into what part of Kodiak Sciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Kodiak Sciences (KOD) is traded on NASDAQ Exchange in USA. It is located in 1200 Page Mill Road, Palo Alto, CA, United States, 94304 and employs 111 people. Kodiak Sciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 304.69 M. Kodiak Sciences runs under Biotechnology sector within Health Care industry. The entity has 52.62 M outstanding shares of which 1.3 M shares are now shorted by investors with about 5.19 days to cover.
Kodiak Sciences has about 597.88 M in cash with (154.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Kodiak Sciences Probability Of Bankruptcy
Ownership AllocationKodiak Sciences maintains a total of 52.62 Million outstanding shares. The majority of Kodiak Sciences outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Kodiak Sciences to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Kodiak Sciences. Please pay attention to any change in the institutional holdings of Kodiak Sciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Kodiak Ownership Details
Kodiak Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Jacobs Levy Equity Management, Inc. | 2024-06-30 | 699.2 K | |
| Board Of Ttees Leland Stanford Jr Univ | 2024-09-30 | 691.8 K | |
| Renaissance Technologies Corp | 2024-09-30 | 607.8 K | |
| Hudson Bay Capital Management Lp | 2024-06-30 | 538.4 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 495.2 K | |
| Ikarian Capital, Llc | 2024-06-30 | 476.6 K | |
| Bruce & Co Inc | 2024-06-30 | 423 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 318.2 K | |
| Two Sigma Advisers, Llc | 2024-06-30 | 300.4 K | |
| Baker Bros Advisors Lp | 2024-09-30 | 17.3 M | |
| Blackrock Inc | 2024-06-30 | 3.8 M |
Kodiak Sciences Historical Income Statement
Kodiak Stock Against Markets
Kodiak Sciences Corporate Management
| Tracy Chien | VP Controller | Profile | |
| Almas MSc | Senior Operations | Profile | |
| Victor MD | Chairman, CoFounder | Profile | |
| Michael Louie | Senior Officer | Profile | |
| CPA MBA | CFO VP | Profile | |
| Pablo MD | Senior Development | Profile | |
| Stephen Raillard | Senior Manufacturing | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kodiak Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Kodiak Stock refer to our How to Trade Kodiak Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kodiak Sciences. If investors know Kodiak will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kodiak Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.64) | Return On Assets (0.27) | Return On Equity (0.71) |
The market value of Kodiak Sciences is measured differently than its book value, which is the value of Kodiak that is recorded on the company's balance sheet. Investors also form their own opinion of Kodiak Sciences' value that differs from its market value or its book value, called intrinsic value, which is Kodiak Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kodiak Sciences' market value can be influenced by many factors that don't directly affect Kodiak Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kodiak Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kodiak Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kodiak Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.